Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Matthew, Zirwas"'
Autor:
Meredith T. Polaskey, Lakshi Aldredge, Candrice Heath, Moises Acevedo, David H. Chu, Diane Hanna, Melissa S. Seal, Matthew Zirwas, Raj Chovatiya
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 11, Pp 3083-3095 (2024)
Abstract Introduction Seborrheic dermatitis (SD) is a common, chronic inflammatory skin disease, but the physical and emotional burden of patients with SD experience has not been well characterized. Methods The Harris Poll conducted online surveys of
Externí odkaz:
https://doaj.org/article/0f68d2175c2247c39d0d18cf56083af1
Autor:
Leon Kircik, Matthew Zirwas, Shawn G. Kwatra, G. Michael Lewitt, Holly Glover, Tomas Chao, Philip M. Brown, David S. Rubenstein, Anna M. Tallman
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 1, Pp 201-211 (2023)
Abstract Introduction Patients with psoriasis report pruritus as their most bothersome symptom. Tapinarof cream 1% once daily demonstrated significant efficacy versus vehicle and was well tolerated in adults with mild to severe plaque psoriasis in tw
Externí odkaz:
https://doaj.org/article/2c5d9e4972684e8faa868f89e77d9aad
Publikováno v:
JAAD Case Reports, Vol 21, Iss , Pp 14-18 (2022)
Externí odkaz:
https://doaj.org/article/3ba19eadd15547809f39ba5e17628902
Autor:
Boni Elewski, Matthew Zirwas, Azra Kurbasic, Shannon Schneider, Ami Claxton, Jonathan Silverberg
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 7:686-695
Background: Tralokinumab, a monoclonal antibody that specifically neutralizes interleukin (IL)-13, is approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD). Tralokinumab was studied in ECZTRA3 (NCT03363854), a randomized
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e16bef10a981e04b50d51f266ed3adfe
https://doi.org/10.25251/skin.7.2.5
https://doi.org/10.25251/skin.7.2.5
Autor:
Melinda Gooderham, Leon Kircik, Matthew Zirwas, Mark Lee, Steven Kempers, Zoe Draelos, Laura Ferris, Terry Jones, Etienne Saint-Cyr Proulx, Robert Bissonnette, Neal Bhatia, Robert Koppel, Scott Guenthner, Kimmie Eads, Howard Welgus, Charlotte Merritt, Meg Elias, Lynn Navale, Robert Higham, Michael Droege, David Berk
Publikováno v:
Journal of Drugs in Dermatology. 22:139-147
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07da9cf4db3997c8a11077dd2a32cd5a
https://doi.org/10.36849/jdd.7295
https://doi.org/10.36849/jdd.7295
Publikováno v:
JAAD Case Reports, Vol 3, Iss 5, Pp 401-403 (2017)
Externí odkaz:
https://doaj.org/article/95b1b1f143f646c484ad6a02848b76e1
Publikováno v:
Journal of the American Academy of Dermatology.
Seborrheic dermatitis (SD) is a common skin disease with signs and symptoms that may vary by skin color, associated medical conditions, environmental factors, and vehicle preference. Diagnosis of SD is based on presence of flaky, "greasy" patches and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16d92fd7f888029650bda05e8399699a
https://pubmed.ncbi.nlm.nih.gov/36538948
https://pubmed.ncbi.nlm.nih.gov/36538948
Autor:
Mark Lebwohl, Linda Stein Gold, Melinda Gooderham, Kim Papp, Laura Ferris, David Adam, H. Chih-ho Hong, Leon Kircik, Matthew Zirwas, Patrick Burnett, Robert Higham, David Krupa, David Berk
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 7:s111
Background: Roflumilast cream is a potent phosphodiesterase 4 inhibitor recently approved in the United States for treatment of plaque psoriasis with no limitations on duration of use. An open-label trial was conducted to evaluate long-term safety (5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc4f922742ab3127a08f61170ad2fea4
https://doi.org/10.25251/skin.7.supp.111
https://doi.org/10.25251/skin.7.supp.111
Autor:
Andrew Blauvelt, Javier Alonso-Llamazares, Neal Bhatia, Zoe Draelos, Janet DuBois, Seth Forman, Melinda Gooderham, Scott Guenthner, Adelaide Hebert, Edward Lain, Angela Moore, Kim Papp, Linda Stein Gold, Matthew Zirwas, Saori Kato, Scott Snyder, David Krupa, Patrick Burnett, David Berk, David Chu
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 7:s196
Introduction: Seborrheic dermatitis (SD) is a common, chronic, inflammatory dermatosis that affects patients of all ages with a global prevalence ≥5%. Treatments usually consist of topical therapies, including antifungals and low potency corticoste
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f22b52dbe2ec81b5a5d395fe1eb1476f
https://doi.org/10.25251/skin.7.supp.196
https://doi.org/10.25251/skin.7.supp.196
Autor:
Jonathan I. Silverberg, David N. Adam, Matthew Zirwas, Sunil Kalia, Jan Gutermuth, Andreas Pinter, Andrew E. Pink, Andrea Chiricozzi, Sebastien Barbarot, Thomas Mark, Ann-Marie Tindberg, Stephan Weidinger
Publikováno v:
American journal of clinical dermatology. 23(4)
The efficacy and safety of tralokinumab, a fully human monoclonal antibody that specifically neutralizes interleukin-13, plus topical corticosteroids (TCS) as needed were evaluated over 32 weeks in the phase III ECZTRA 3 trial. Significantly more tra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12337bc7c464140498adda698996f7a8
https://pubmed.ncbi.nlm.nih.gov/35857179
https://pubmed.ncbi.nlm.nih.gov/35857179